Then, we further evaluated the levels of NSE, Cyfra21-1, CA19-9, CEA, TrxR and combinations thereof in a large clinical population to improve the efficiency of NSCLC diagnosis for future clinical application. This evidence concerns the gene ENO2 and non-small cell lung carcinoma.